Baucus Bill Takes “Patient-Centered” Focus For Comparative Effectiveness
This article was originally published in The Tan Sheet
Executive Summary
The latest comparative effectiveness legislation from Sen. Max Baucus suggests an approach that might be more welcome to the pharma industry
You may also be interested in...
Senate Revises Comparative Effectiveness Plan In Reform Bill
Comparative effectiveness research that Senate Finance Committee Chairman Max Baucus envisioned - led by a non-government institute with funding from public and private sources - is among the health care reform provisions being debated
Comparative Effectiveness Bill Allows Industry Input Into Study Selection
A bill introduced in the House would prevent the government from being the sole director of comparative effectiveness research by setting up an independent institute overseen by a broad array of stakeholders, including industry
Baucus Maintains Public/Private Comparative Effectiveness Vision
Senate Finance Committee Chairman Max Baucus continues planning to include comparative effectiveness in the health care reform debate, even with research funding included in the American Recovery and Reinvestment Act